Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. on October 13, 2016. The filing serves to disclose a press release regarding a regulatory and clinical update for the company's nocturnal leg cramp program. The registrant is incorporated in Delaware and maintains its principal executive offices in Boston, MA.
Financial Metrics
The filing text does not provide specific financial data. As this is a current report focused on a specific event (Item 8.01), it does not contain revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The material event reported is the issuance of a press release on October 13, 2016, detailing a regulatory and clinical update for the company's nocturnal leg cramp treatment. No financial material changes are reported in this document.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release (Exhibit 99.1) containing the clinical and regulatory update. The text of the 8-K itself does not provide specific guidance, management commentary, risk factors, or details on unusual items beyond the reference to the press release.
Key Facts for Investor Verification
- Verify the specific details of the nocturnal leg cramp regulatory and clinical update by reviewing Exhibit 99.1 (Press Release dated October 13, 2016) attached to this filing.
- Note that this filing contains no financial statements or quantitative performance metrics.
- Confirm the company's current status regarding its principal executive offices in Boston, MA.